A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

NCT03131206 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Study closed due to slow accrual and lack of efficacy.

Conditions

ALK-positive Non-small Cell Lung Cancer (NSCLC)
RET-positive Non-small Cell Lung Cancer (NSCLC)
RET-positive Thyroid Cancer

Interventions

DRUG: Alectinib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]